<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9791">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690087</url>
  </required_header>
  <id_info>
    <org_study_id>36204/12/22</org_study_id>
    <nct_id>NCT05690087</nct_id>
  </id_info>
  <brief_title>Lidocaine Infusion on Optic Nerve Sheath Diameter in Laparoscopic Hysterectomy in Trendelenburg Position</brief_title>
  <official_title>Effect of Systemic Lidocaine Infusion on Optic Nerve Sheath Diameter in Patients Undergoing Laparoscopic Hysterectomy in Trendelenburg Position</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that intravenous lidocaine infusion may have beneficial effect to patients&#xD;
      undergoing laparoscopic surgeries in Trendelenburg position by preventing ICP elevation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lidocaine use, both intravenous (IV) and laryngotracheal (LT), has been reported to blunt the&#xD;
      ICP elevations during intubation. Also, Lidocaine injected IV has been shown in models to&#xD;
      induce cerebral vasoconstriction leading to a decrease in cerebral blood volume and thus ICP.&#xD;
      Furthermore, IV lidocaine leads to sodium channel inhibition and thus a reduction in cerebral&#xD;
      activity and metabolic demands, as well as excitotoxicity, leading to a potential ICP&#xD;
      reduction effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2023</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optic Nerve Sheath Diameter (ONSD)</measure>
    <time_frame>5 min before induction of anesthesia till 5 min after the closure of pneumoperitoneum</time_frame>
    <description>ONSD at 5 min before induction of anesthesia in supine position (T1), 5 min after CO2 pneumoperitoneum in Trendelenburg position (T2), 30 min after CO2 pneumoperitoneum in Trendelenburg position (T3), 60 min after CO2 pneumoperitoneum in Trendelenburg position (T4) and 5 min after the closure of pneumoperitoneum in supine position (T5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>5 min before induction of anesthesia till 5 min after the closure of pneumoperitoneum</time_frame>
    <description>Heart rate at 5 min before induction of anesthesia in supine position (T1), 5 min after CO2 pneumoperitoneum in Trendelenburg position (T2), 30 min after CO2 pneumoperitoneum in Trendelenburg position (T3), 60 min after CO2 pneumoperitoneum in Trendelenburg position (T4) and 5 min after the closure of pneumoperitoneum in supine position (T5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>5 min before induction of anesthesia till 5 min after the closure of pneumoperitoneum</time_frame>
    <description>Mean arterial blood pressure at 5 min before induction of anesthesia in supine position (T1), 5 min after CO2 pneumoperitoneum in Trendelenburg position (T2), 30 min after CO2 pneumoperitoneum in Trendelenburg position (T3), 60 min after CO2 pneumoperitoneum in Trendelenburg position (T4) and 5 min after the closure of pneumoperitoneum in supine position (T5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of postoperative adverse reactions</measure>
    <time_frame>Within 3 hours after surgery</time_frame>
    <description>The incidence of adverse reactions, such as dizziness, postoperative nausea and vomiting (PONV) and postoperative headache (POHA) within 3 hours after surgery will be recorded in both groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Lidocaine</condition>
  <condition>Optic Nerve Sheath Diameter</condition>
  <condition>Laparoscopic Hysterectomy</condition>
  <condition>Trendelenburg</condition>
  <arm_group>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous sodium chloride 0.9% solution volume matched in bolus and infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation</description>
    <arm_group_label>Lidocaine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride 0.9% solution</intervention_name>
    <description>intravenous sodium chloride 0.9% solution volume matched bolus and infusion.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 35 to 65 years&#xD;
&#xD;
          -  American society of anesthesiology (ASA) physical status I - II&#xD;
&#xD;
          -  Body mass index (BMI) between 18.5 to 28.0 kg/m2&#xD;
&#xD;
          -  Scheduled for total laparoscopic hysterectomy taking approximately 2 h with a 30Â°&#xD;
             Trendelenburg position for management of uterine fibroids or refractory dysfunctional&#xD;
             uterine bleeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with eye diseases, central nervous system diseases, cardiovascular diseases,&#xD;
             cerebrovascular diseases or diabetes.&#xD;
&#xD;
          2. If these events occurred intraoperative:&#xD;
&#xD;
               -  Ultrasound scans or measurements failed to clearly show the structure of Optic&#xD;
                  Nerve Sheath Diameter (ONSD).&#xD;
&#xD;
               -  Surgical time less than 1 h.&#xD;
&#xD;
               -  Interruption of carbon dioxide (CO2) pneumoperitoneum and Trendelenburg position.&#xD;
&#xD;
               -  Peak airway pressure exceeding 35 cm H2O&#xD;
&#xD;
          3. Patients with a history of allergy to lidocaine.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients scheduled for laparoscopic hysterectomy surgery.</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Osama M Rehab, MD</last_name>
    <phone>00201095210806</phone>
    <email>osamarehab@med.tanta.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta University Hospitals</name>
      <address>
        <city>Tanta</city>
        <state>ElGharbiaa</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama M Rehab, MD</last_name>
      <phone>00201095210806</phone>
      <email>osamarehab@med.tanta.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>March 5, 2023</last_update_submitted>
  <last_update_submitted_qc>March 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Osama Rehab</investigator_full_name>
    <investigator_title>Lecturer of Anesthesiology, Intensive Care and Pain Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be available upon reasonable request from the corresponding author</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>After completion of the study</ipd_time_frame>
    <ipd_access_criteria>The data will be available upon reasonable request from the corresponding author</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

